

Interplay between hypercholesterolemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice.

José Tuñón^{1*}, Magnus Bäck^{2,3*}, Lina Badimón⁴, Marie-Luce Bochaton-Piallat⁵, Bertrand Cariou⁶, Mat J Daemen⁷, Jesus Egido⁸, Paul C Evans⁹, Sheila E. Francis⁹, Daniel FJ Ketelhuth³, Esther Lutgens^{7,10,11}, Christian M. Matter¹³, Claudia Monaco¹⁴, Sabine Steffens¹¹, Erik Stroes⁷, Cécile Vindis¹⁵, Christian Weber^{11,12}, and Imo E Hoefer¹⁶, on behalf of the ESC Working Group on Atherosclerosis and Vascular Biology

¹Fundación Jiménez Díaz, Autónoma University and CiberCV, Madrid, Spain

²Karolinska University Hospital, Stockholm, Sweden

³Karolinska Institutet, Stockholm, Sweden

⁴Cardiovascular Sciences Institute (ICCC) and CiberCV, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

⁵University of Geneva, Geneva, Switzerland

⁶L'Institut du Thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France

⁷Academic Medical Center, Amsterdam, The Netherlands

⁸Fundación Jiménez Díaz, Autónoma University and CIBERDEM, Madrid, Spain

⁹University of Sheffield, Sheffield, UK

¹⁰University of Amsterdam, Amsterdam, The Netherlands

¹¹Institute for Cardiovascular Prevention, LMU Munich and German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany

¹²Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands

¹³University Heart Center, University Hospital Zurich and Center for Molecular Cardiology, University of Zurich, Zurich, Switzerland

¹⁴Kennedy Institute, NDORMS, University of Oxford, UK

¹⁵INSERM UMR-1048, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France

¹⁶University Medical Centre Utrecht, Netherlands

*Equal contribution

This paper has not been presented previously in any Congress and it has not been published in any scientific journal

Word Count: 5,095 with two figures.

FUNDING

JT is funded by FIS (PI14/01567 and PI17/01615) and the Spanish Society of Cardiology

MB is funded by Swedish Research Council (2014-2312); and the Swedish Heart and Lung Foundation (20150600 and 20150683).

LB is funded by PNS-2016 from MINECO, Tercel 2016 and CiberCV from Institute Carlos III.

BC is funded by Fondation Leducq (13CVD03).

PCE and SEF are funded by the British Heart Foundation.

JE is funded by FIS-FEDER (PI14/00386).

DFJK is supported by the Swedish Heart-Lung Foundation and Novo Nordisk Foundation (NNF15CC0018346).

CMM is funded by the Swiss National Science Foundation.

EL is funded by the NWO (VICI), the European Research Council (ERC-con) and the DFG (SFB1123).

SS is supported by the DFG (STE1053/3-1 and 5-1).

CW is funded by the European Research Council (ERC-Adv) and the DFG (SFB1123).

Correspondence address:

José Tuñón

Department of Cardiology, Fundación Jiménez Díaz

Avenida Reyes Católicos 2, 28040 Madrid, Spain

Phone: +34915504800 Ext 3701

Email: jtunon@fjd.es

ABSTRACT

Dyslipidemia and inflammation are closely interconnected in their contribution to atherosclerosis. In fact, low-density lipoprotein (LDL)-lowering drugs have anti-inflammatory effects. The Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS), has shown that IL (interleukin)-1 β blockade reduces the incidence of cardiovascular events in patients with previous myocardial infarction and C-reactive protein (CRP) levels >2 mg/L. These data confirm the connection between lipids and inflammation, as lipids activate the Nod-like receptor protein 3 (NLRP3) inflammasome that leads to IL-1 β activation.

LDL-lowering drugs are the foundation of cardiovascular prevention. Now, the CANTOS trial demonstrates that combining them with IL-1 β blockade further decreases the incidence of cardiovascular events. However, both therapies are not at the same level, given the large evidence showing that LDL-lowering drugs reduce cardiovascular risk as opposed to only one randomized trial of IL-1 β blockade. In addition, IL-1 β blockade has only been studied in patients with CRP >2 mg/L, while the benefit of LDL-lowering is not restricted to these patients. Also, lipid-lowering drugs are not harmful even at very low ranges of LDL, while anti-inflammatory therapies may confer a higher risk of developing fatal infections and sepsis.

In the future, more clinical trials are needed to explore if targeting other inflammatory molecules, both related and unrelated with the IL-1 β pathway, reduces the cardiovascular risk. In this regard, the ongoing trials with methotrexate and colchicine may clarify if the cardiovascular benefit of IL-1 β blockade extends to other anti-inflammatory mechanisms. A positive result would represent a major change in the future treatment of atherosclerosis.

Keywords: Lipids, Inflammation, Immune response, atherosclerosis, interleukin-1 β , canakinumab

INTRODUCTION

Lipids play a pivotal role in atherosclerosis. Inflammation has also been acknowledged as a key biological process in this disorder¹. Importantly, dyslipidemia and inflammation are closely intertwined in their contribution to atherosclerosis and cardiovascular (CV) risk². Hence, low-density lipoprotein (LDL)-lowering drugs that effectively decrease CV events have also anti-inflammatory effects³. However, some of the anti-inflammatory effects reported for statins, and also for aspirin and renin-angiotensin modulators³⁻⁵, may result from LDL-lowering, antithrombotic or anti-proliferative effects, and from an improved endothelial function.

Observational studies have suggested beneficial effects of anti-inflammatory drugs in terms of CV risk reduction⁶. However, until recently, evidence on the efficacy of anti-inflammatory strategies to reduce CV events in humans was lacking. Thus, there was a need for a definitive study to specifically address the potential influence of inflammatory suppression on the incidence of CV events.

The recent Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS) has shown, in patients on statin therapy but with elevated C-reactive protein (CRP) levels, a significant reduction of CV events by the inhibition of interleukin-1 β (IL-1 β) without further influencing lipid levels⁷. These results introduce a new paradigm for the treatment of human atherosclerosis and CV disease. In this Consensus Paper, we highlight the role of inflammation and dyslipidemia in atherosclerosis and aim to outline the new issues and challenges that are brought up by the interplay between these two risk factors in CV prevention.

LIPID-INDUCED INFLAMMATORY RESPONSES (Figure 1)

A key trigger of atherosclerosis is subintimal retention of LDL at regions of complex flow or low shear stress⁸. Modified LDL are strong inducers of inflammation

and have a marked impact on atherosclerosis. They alter vascular physiology by activating pattern recognition receptors, such as toll-like receptors (TLRs), which trigger proinflammatory signals and reactive oxygen species and promote matrix degradation⁹⁻¹². These TLRs will prime the Nod-like receptor protein 3 (NLRP3) inflammasome for activation by cholesterol crystals leading to IL-1 β activation¹³ (Figure 2). This leads to the increased release of cytokines and activates the endothelium by enhancing the expression of adhesion molecules and chemokines, costimulatory molecules, such as CD40, and pro-inflammatory transcription factors as nuclear factor- κ B (NF- κ B)¹⁴⁻¹⁶, promoting the recruitment of inflammatory cells into the vascular wall. Among them, macrophages are of key relevance since they can scavenge oxidized LDL¹⁷ evolving into pro-atherogenic foam cells^{1,6,18}. Also, in atherosclerosis there is an enhanced haematopoietic activity in the bone marrow and LDL stimulates the capacity of hematopoietic stem and progenitor cells to differentiate into inflammatory cells¹⁹.

Adaptive immune responses play a key role in atherogenesis. Activated T lymphocytes are present in both peripheral blood and coronary atherosclerotic plaques in patients with acute coronary syndromes^{1,20}, and especially Th1 (T helper h1)-derived cytokines such as TNF α (tumour necrosis factor α), and interferon-gamma are associated with atherosclerosis. The notion of immunomodulatory effects of LDL-lowering agents emerged from both experimental and clinical studies^{21,22}, thus, the causal relation between lipids and immunity with regard to atherogenesis has been heavily investigated in the recent two decades.

ANTI-INFLAMMATORY EFFECTS OF LDL-LOWERING THERAPIES

There is overwhelming evidence indicating that statins have anti-inflammatory and immunomodulatory effects. They decrease the activity of the transcription factor

NF- κ B³, with subsequent diminution in the expression of adhesion molecules, cytokines²³ and MMPs, interfering also with the arachidonic/cyclooxygenase pathway²⁴. Also, they reduce plasma levels of inflammatory markers such as CRP²⁵. Although most evidence has been obtained with statins, other LDL-lowering approaches have shown some anti-inflammatory effects. For instance, ezetimibe and fibrates also inhibit the NF- κ B pathway and decrease CRP levels²⁶⁻²⁹. Similarly, low fat diet reduces CRP levels³⁰ and Mediterranean diet, which decreases LDL/HDL (high-density lipoprotein) cholesterol ratio³¹, reduces CD40 expression on monocytes and plasma levels of cell adhesion molecules and cytokines³².

Recently, another class of LDL-lowering drugs, Proprotein convertase subtilisin/kexin type 9 (PCSK9) human monoclonal antibodies (mab), has demonstrated to reduce the incidence of CV events^{33,34}. PCSK9 mab do not decrease plasma levels of CRP and other inflammatory markers,³⁵⁻³⁷. However, they reduce levels of Lipoprotein (a)³⁸ -a molecule that promotes inflammation, oxidative stress, and coagulation- and decrease monocyte activation and transmigration in patients with familial hypercholesterolemia³⁵. Moreover, PCSK9 inhibition in atherosclerotic mice, diminished macrophage and necrotic core content³⁹. These findings suggest that plasma biomarkers may not always represent an exact indicator of the degree of inflammation at the arterial wall. In addition, up-regulation of hepatic LDL receptors (LDLR) by PCSK9 inhibition results in increased lipopolysaccharide clearance, and decreased inflammatory response during sepsis in mice^{40,41}. In this regard, patients with PCSK9 loss-of-function variants exhibit improved clinical outcomes during septic shock⁴².

Likewise, PCSK9 expression can be experimentally induced by pro-inflammatory molecules, such as lipopolysaccharide and TNF α among others^{43,44}. Also, PCSK9 modulates LDLR expression in macrophages,⁴⁵ promoting the expression of pro-inflammatory markers, and inhibiting anti-inflammatory molecules⁴⁵. In humans,

plasma PCSK9 concentrations are positively associated with white blood cell count and fibrinogen in patients with coronary artery disease⁴⁶. Then, these evidences show that other LDL-lowering therapies than statins can decrease inflammation.

ANTI-INFLAMMATORY THERAPY AND CARDIOVASCULAR RISK

Inflammatory cytokines such as IL-1 β ⁴⁷ and TNF- α ⁴⁸ have been detected in human coronary atherosclerosis. Observational studies have revealed an association of different anti-inflammatory treatments, when used for their indications, with reduced CV risk, providing support for the concept of inflammation reduction in CV prevention⁶. This is the case for anti-TNF therapy in rheumatoid arthritis^{49,50} and anti-leukotrienes in asthmatics⁵¹ that apparently decreased the incidence of CV events but were never tested in randomized clinical trials. On the other hand, other anti-inflammatory drugs failed to decrease the CV risk, as was observed for steroids in patients with unstable angina⁵². However, large studies and clinical trials until now have shown that, with the exception of aspirin, non-steroidal anti-inflammatory drugs in general are associated with an increased CV risk⁵³⁻⁵⁶, indicating that their use should be limited to patients without other alternatives⁵⁴.

The recent CANTOS trial sheds new light in the relationship of inflammation with atherosclerosis⁷. In this randomized, double-blind trial, 10,061 patients with a previous myocardial infarction, majority using moderate to high intensity statin therapy, and CRP>2 mg/L received canakinumab, a monoclonal antibody that blocks IL-1 β , or placebo. After a median follow-up of 3.7 years there was a ~15% decrease in the incidence of the primary end point composed of nonfatal myocardial infarction and nonfatal stroke. While there was an increase in the incidence of fatal infections, neutropenia or thrombocytopenia in patients on canakinumab, there were also non-CV benefits, comprising a reduction in the incidence of lung cancer, cancer mortality,

arthritis, and gout, although no difference in total mortality was observed between groups^{7,57}.

IMPACT OF THE CANTOS TRIAL ON OUR UNDERSTANDING OF INTERPLAY BETWEEN LIPIDS AND INFLAMMATION

In addition to demonstrate that targeting inflammation can be effective in the treatment of atherosclerosis, the results from the CANTOS trial provide a first proof of principle about the link between lipids and inflammation. As mentioned above, cholesterol crystals activate the NLRP3 inflammasome, leading to IL1 β activation¹³ (Figure 2) and non-canonical pathways of activation also exist⁵⁸. Since IL-1 can activate itself⁵⁹, blocking this pathway with canakinumab could attenuate this effect of lipids.

Interestingly, it has been shown that inflammation can induce dyslipidemia through different mechanisms^{60,61}. However, the effects of anti-inflammatory and immunosuppressive therapies on lipids are variable with both favourable and adverse lipid profiles having been reported⁶²⁻⁶⁴, probably depending of the population studied and the drug used⁶³. In this trial, canakinumab did not decrease lipid levels, while increased slightly triglyceride levels⁵⁷. Thus, the CANTOS data exclude the possibility that canakinumab reduces CV-risk through lipid-dependent mechanisms linked to IL-1 β .

Patients in the CANTOS trial had mean LDL levels of approximately 80 mg/dl and CRP>2 mg/L. Efforts to further reduce residual CV-risk now have multiple options. The prespecified analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) study showed that the CV-benefit of LDL lowering with PCSK9 mab is extended to very low LDL values, finding a 31% reduction in the incidence of the primary end point in patients achieving levels of 10 mg/dl as compared to those with 100 mg/dl or higher⁶⁵. Similarly,

CANTOS demonstrates that in patients showing a reduction of CRP levels below 2 mg/L following canakinumab administration, a 31% risk reduction in both total and CV mortality is observed as compared to no benefit in those with CRP levels of 2 mg/L or above⁶⁶. However, the large body of evidence linking LDL-lowering to a reduction in CV risk clearly favours the use of PCSK9 mab^{33,67}. In the future, it would be interesting to explore the CV effect of other anti-inflammatory therapies including those directed at regulating IL-1 e.g Anakinra⁶⁸ or other upstream IL-1 related molecules⁶⁹. In this regard, the Colchicine Cardiovascular Outcomes Trial (COLCOT) (<https://clinicaltrials.gov/ct2/show/NCT02551094>) and the Cardiovascular Inflammation Reduction Trial (CIRT)⁷⁰ are investigating whether colchicine and methotrexate, respectively, reduce the incidence of CV events in patients with coronary artery disease. Finally, the benefit of canakinumab was demonstrated in patients with high CRP levels but its effects in patients with low CRP remain to be established, while that of LDL-lowering drugs does not seem to be restricted to this subgroup. Although lipid-lowering therapy is not free of adverse effects⁷¹, it has been consistently demonstrated that it is a safe therapy, and even achieving very low LDL levels shows an acceptable risk/benefit balance⁶⁵. On the other hand IL-1 β blockade may confer a higher risk of developing fatal infections and sepsis⁷ and requires further study due the scarce amount of information available regarding this point.

Finally, the inclusion criteria of CRP>2 mg/L in CANTOS, and the subgroup analysis performed according to CRP in this trial underline the need to improve risk stratification in patients with atherosclerosis. In addition to assessing LDL levels, it is true that CRP levels and even IL-1 β genotype⁷² have been suggested to guide personalized medicine in an effort to further reduce the residual burden in high CV-risk patients. However, the role of these and other inflammatory biomarkers or even imaging strategies to better select high-responders to therapeutic moieties targeting either

residual lipid or inflammatory pathways remains to be established⁷³ and their use is not recommended at present⁷⁴⁻⁷⁵.

CONCLUDING REMARKS AND OPEN QUESTIONS

1. Interplay between lipids and inflammation: The reduction in CV events observed with IL-1 β blockade confirms the link between lipids and inflammation. The mechanism involves cholesterol crystals (and possibly other lipid species) that activate major inflammatory pathways (TLRs or the NLRP3) inducing maturation and release of IL-1 β , which is blocked by canakinumab.

2. Other pro-inflammatory targets appear worth testing. Although IL-1 β blockade is today the only anti-inflammatory approach shown to significantly reduce CV risk in a randomized clinical trial for patients with CV disease, the wealth of evidence linking inflammation with atherosclerosis indicates that other potential targets exist to be evaluated in future trials. In addition, other tools than antibodies, such as interference RNAs, may be tested to inhibit IL1 β .

3. Anti-inflammatory vs LDL-lowering therapy in CV prevention. Canakinumab is not a competitor of LDL-lowering therapies given, among other reasons, that the large evidence supporting these therapies cannot be compared with the results of only one clinical trial.

4. Potential role of anti-inflammatory therapy in CV prevention. Although the results of CANTOS trial can be considered a milestone in CV medicine, canakinumab prescription for patients with CV risk to improve their prognosis needs to overcome some certain hurdles. In this regard, the results of the ongoing CIRT and COLCOT trials will clarify if the cardiovascular benefit of IL1 β blockade extends to other anti-inflammatory drugs that work through different mechanisms, as this could represent a change in the horizon of the treatment of atherosclerosis.

DISCLOSURES

Dr. Tuñón reports personal fees from Sanofi-Regeneron, Amgen, and Pfizer.

Dr. Badimon reports personal fees from Sanofi and Amgen, and grants and personal fees from AstraZeneca.

Dr. Cariou reports grants from Pfizer, personal fees from Amgen and MSD (Merck), and grants and personal fees from Sanofi-Regeneron.

Dr. Egido reports personal fees from Sanofi and Pfizer, outside the submitted work.

Dr. Francis reports limited stocks holdings from Interleukin Genetics Inc, a patent EP1409737 A4 issued to Interleukin Genetics Inc, and a patent WO2000072015A3 issued to Medical Science Systems.

Dr. Matter reports grants from Swiss National Science Foundation, Roche, EliLilly, Amgen, AstraZeneca, Sanofi, and personal fees from MSD, AstraZeneca, Roche Sanofi and Amgen.

Dr. Monaco reports grants from European Commission, non-financial support from Harrington Discovery Institute, grants from Novo Nordisk Foundation and a patent GB 1022049.9 (ICOBV/P47994GB) issued to Monaco/Feldmann.

Dr. Stroes reports lecturing and board fees from Amgen, Sanofi Regeron, Akcea, Esperion, and Athera.

The remaining authors have nothing to disclose.

AUTHOR CONTRIBUTION

JT: Contributed to conception and design, drafted the manuscript, critically revised the manuscript, gave final approval and agrees to be accountable for all aspects of work ensuring integrity and accuracy.

MB, BC, DK and CM: Contributed to conception and design, drafted the manuscript, critically revised the manuscript, and gave final approval.

LB, MB-P, MD, JE, PE, SF, EL, CM, SS, ES, CV, CW and IH: Contributed to conception and design, drafted the manuscript, critically revised the manuscript, and gave final approval.

REFERENCES

1. Libby P. Inflammation in Atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology* 2012;32:2045-2051.
2. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. *Nat Med* 2011;17:1410-1422.
3. Bustos C, Hernández-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. *Journal of the American College of Cardiology* 1998;32:2057-2064.
4. Hernández-Presa M, Bustos C, Ortego M, et al. Angiotensin-Converting Enzyme Inhibition Prevents Arterial Nuclear Factor- κ B Activation, Monocyte Chemoattractant Protein-1 Expression, and Macrophage Infiltration in a Rabbit Model of Early Accelerated Atherosclerosis. *Circulation* 1997;95:1532-1541.
5. Weber C, Erl W, Pietsch A, et al. Aspirin Inhibits Nuclear Factor- κ B Mobilization and Monocyte Adhesion in Stimulated Human Endothelial Cells. *Circulation* 1995;91:1914-1917.
6. Back M, Hansson GK. Anti-inflammatory therapies for atherosclerosis. *Nat Rev Cardiol* 2015;12:199-211.
7. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *New England Journal of Medicine* 2017;377:1119-1131.
8. Kwak BR, Back M, Bochaton-Piallat ML, et al. Biomechanical factors in atherosclerosis: mechanisms and clinical implications. *Eur Heart J* 2014;35:3013-20, 3020a-3020d.
9. Cole JE, Kassiteridi C, Monaco C. Toll-like receptors in atherosclerosis: a 'Pandora's box' of advances and controversies. *Trends Pharmacol Sci* 2013;34:629-636.

10. Miller YI, Viriyakosol S, Binder CJ, et al. Minimally Modified LDL Binds to CD14, Induces Macrophage Spreading via TLR4/MD-2, and Inhibits Phagocytosis of Apoptotic Cells. *Journal of Biological Chemistry* 2003;278:1561-1568.
11. Monaco C, Gregan SM, Navin TJ, et al. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. *Circulation* 2009;120:2462-2469.
12. Badimon L. Interleukin-18: a potent pro-inflammatory cytokine in atherosclerosis. *Cardiovascular Research* 2012;96:172-175.
13. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. *Nature* 2010;464:1357-1361.
14. Barnes PJ, Karin M. Nuclear Factor- κ B — A Pivotal Transcription Factor in Chronic Inflammatory Diseases. *New England Journal of Medicine* 1997;336:1066-1071.
15. Xu X-P, Meisel SR, Ong JM, et al. Oxidized Low-Density Lipoprotein Regulates Matrix Metalloproteinase-9 and Its Tissue Inhibitor in Human Monocyte-Derived Macrophages. *Circulation* 1999;99:993-998.
16. Badimon L, Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture. *Journal of Internal Medicine* 2014;276:618-632.
17. Llorente-Cortés V, Royo T, Otero-Viñas M, et al. Sterol regulatory element binding proteins downregulate LDL receptor-related protein (LRP1) expression and LRP1-mediated aggregated LDL uptake by human macrophages. *Cardiovascular Research* 2007;74:526-536.
18. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. *Cell* 2011;145:341-355.
19. van der Valk FM, Kuijk C, Verweij SL, et al. Increased haematopoietic activity in patients with atherosclerosis. *Eur Heart J* 2017;38:425-432.

20. Seneri GG, Abbate R, Gori AM, et al. Transient intermittent lymphocyte activation is responsible for the instability of angina. *Circulation* 1992;86:790-797.
21. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. *Nat Med* 2000;6:1399-1402.
22. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of Pravastatin on Outcomes after Cardiac Transplantation. *New England Journal of Medicine* 1995;333:621-627.
23. Martínez-González J, Alfón J, Berrozpe M, et al. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. *Atherosclerosis* 2001;159:27-33.
24. Gómez-Hernández A, Sánchez-Galán E, Ortego M, et al. Effect of Intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-Elevation Acute Coronary Syndrome. *American Journal of Cardiology* 2008;102:12-18.
25. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events. *New England Journal of Medicine* 2001;344:1959-1965.
26. Qin L, Yang YB, Yang YX, et al. Anti-Inflammatory Activity of Ezetimibe by Regulating NF-kB/MAPK Pathway in THP-1 Macrophages. *Pharmacology* 2014;93:69-75.
27. Chan DC, Watts GF, Gan SK, et al. Effect of Ezetimibe on Hepatic Fat, Inflammatory Markers, and Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Subjects on a Weight Loss Diet. *Diabetes Care* 2010;33:1134-1139.

28. Delerive P, De Bosscher K, Besnard S, et al. Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF- κ B and AP-1. *Journal of Biological Chemistry* 1999;274:32048-32054.
29. Krysiak R, Gdula-Dymek A, Okopien B. The Effect of Fenofibrate on Lymphocyte Release of Proinflammatory Cytokines and Systemic Inflammation in Simvastatin-Treated Patients with Atherosclerosis and Early Glucose Metabolism Disturbances. *Basic & Clinical Pharmacology & Toxicology* 2013;112:198-202.
30. Camhi SM, Stefanick ML, Ridker PM, et al. Changes in C-Reactive Protein from Low-Fat Diet and/or Physical Activity in Men and Women With and Without Metabolic Syndrome. *Metabolism: clinical and experimental* 2010;59:54-61.
31. Fitó M, Guxens M, Corella D, et al; PREDIMED Study Investigators. Effect of a traditional Mediterranean diet on lipoprotein oxidation: a randomized controlled trial. *Arch Intern Med* 2007;167:1195-1203.
32. Casas R, Sacanella E, Urpí-Sardà M, et al. The Effects of the Mediterranean Diet on Biomarkers of Vascular Wall Inflammation and Plaque Vulnerability in Subjects with High Risk for Cardiovascular Disease. A Randomized Trial. *PLoS ONE* 2014;9:e100084.
33. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *New England Journal of Medicine* 2017;376:1713-1722.
34. Robinson JG, Farnier M, Krempf M, et al. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. *New England Journal of Medicine* 2015;372:1489-1499.

35. Bernelot Moens SJ, Neele AE, Kroon J, et al. PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia. *European Heart Journal* 2017;38:1584-1593.
36. Sahebkar A, Di Giosia P, Stamerra CA, et al. Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms. *British Journal of Clinical Pharmacology* 2016;81:1175-1190.
37. Baruch A, Mosesova S, Davis JD, Budha N, Vilimovskij A, Kahn R, Peng K, Cowan KJ, Harris LP, Gelzleichter T, Lehrer J, Davis JC, Jr., Tingley WG. Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study). *American Journal of Cardiology*;119:1576-1583.
38. Gaudet D, Kereiakes DJ, McKenney JM, et al. Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials). *American Journal of Cardiology* 2014;114:711-715.
39. Kühnast S, van der Hoorn JWA, Pieterman EJ, et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. *Journal of Lipid Research* 2014;55:2103-2112.
40. Topchiy E, Cirstea M, Kong HJ, et al. Lipopolysaccharide Is Cleared from the Circulation by Hepatocytes via the Low Density Lipoprotein Receptor. *PLoS ONE* 2016;11:e0155030.
41. Dwivedi DJ, Grin PM, Khan M, et al. Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis. *Shock* 2016;46:672-680.

42. Walley KR, Thain KR, Russell JA, et al. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. *Science translational medicine* 2014;6:258ra143-258ra143.
43. Ruscica M, Ricci C, Macchi C, et al. Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line. *Journal of Biological Chemistry* 2016;291:3508-3519.
44. Feingold KR, Moser AH, Shigenaga JK, et al. Inflammation stimulates the expression of PCSK9. *Biochemical and Biophysical Research Communications* 2008;374:341-344.
45. Giunzioni I, Tavori H, Covarrubias R, et al. Local effects of human PCSK9 on the atherosclerotic lesion. *The Journal of Pathology* 2016;238:52-62.
46. Li S, Guo Y-L, Xu R-X, et al. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. *Atherosclerosis* 2014;234:441-445.
47. Galea J, Armstrong J, Gadsdon P, et al. Interleukin-1 β in Coronary Arteries of Patients With Ischemic Heart Disease. *Arteriosclerosis, Thrombosis, and Vascular Biology* 1996;16:1000-1006.
48. Kaartinen M, Penttilä A, Kovanen PT. Mast Cells in Rupture-Prone Areas of Human Coronary Atheromas Produce and Store TNF- α . *Circulation* 1996;94:2787-2792.
49. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. *Arthritis Care Res (Hoboken)* 2011;63:522-529.
50. Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. *J Rheumatol* 2005;32:1213-1218.

51. Ingelsson E, Yin L, Bäck M. Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. *Journal of Allergy and Clinical Immunology*;129:702-707.e2.
52. Azar RR, Rinfret S, Thérioux P, et al. A randomized placebo-controlled trial to assess the efficacy of antiinflammatory therapy with methylprednisolone in unstable angina (MUNA trial). *European Heart Journal* 2000;21:2026-2032.
53. McGettigan P, Henry D. Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. *PLOS Medicine* 2011;8:e1001098.
54. Antman EM, Bennett JS, Daugherty A, et al. Use of Nonsteroidal Antiinflammatory Drugs. An Update for Clinicians: A Scientific Statement From the American Heart Association. *Circulation* 2007;115:1634-1642.
55. Bäck M, Yin L, Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. *European Heart Journal* 2012;33:1928-1933.
56. Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. *New England Journal of Medicine* 2016;375:2519-2529.
57. Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1 β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. *The Lancet* 2017;390:1833-1842.
58. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. *Blood* 2011;117:3720-3732.

59. Dinarello CA, Ikejima T, Warner SJ, et al. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. *The Journal of Immunology* 1987;139:1902-1910.
60. Khovidhunkit W, Kim MS, Memon RA, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. *J Lipid Res* 2004;45:1169-1196.
61. Klingenberg R, Gerdes N, Badeau RM, et al. Depletion of FOXP3⁺ regulatory T cells promotes hypercholesterolemia and atherosclerosis. *The Journal of Clinical Investigation* 2013;123:1323-1334.
62. Georgiadis AN, Papavasiliou EC, Lourida ES, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study. *Arthritis Res Ther* 2006;8:R82.
63. Saiki O, Takao R, Naruse Y, et al. Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis. *J Rheumatol* 2007;34:1997-2004.
64. Simha V, Qin S, Shah P, et al. Sirolimus Therapy Is Associated with Elevation in Circulating PCSK9 Levels in Cardiac Transplant Patients. *Journal of Cardiovascular Translational Research* 2017;10:9-15.
65. Giugliano RP, Pedersen TR, Park J-G, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. *The Lancet* 2017;390:1962-1971.
66. Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ; CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. *Lancet* 2018;391:319-328.

67. Silverman MG, Ference BA, Im K, et al. Association between lowering ldl-c and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis. *JAMA* 2016;316:1289-1297.
68. Morton AC, Rothman AMK, Greenwood JP, et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. *European Heart Journal* 2015;36:377-384.
69. Smith SA, Samokhin AO, Alfadi M, et al. The IL-1RI Co-Receptor TILRR (FREM1 Isoform 2) Controls Aberrant Inflammatory Responses and Development of Vascular Disease. *Jacc Basic to Translational Science* 2017;2:398-414.
70. Everett BM, Pradhan AD, Solomon DH, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. *Am Heart J* 2013;166:199-207.
71. Stroes ES, Thompson PD, Corsini A, et al; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. *Eur Heart J* 2015;36:1012-1022.
72. Tsimikas S, Duff GW, Berger PB, et al. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). *J Am Coll Cardiol* 2014;63:1724-1734.
73. Hoefer IE, Steffens S, Ala-Korpela M, et al. Novel methodologies for biomarker discovery in atherosclerosis. *Eur Heart J* 2015;36:2635-2642.
74. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the

European Society of Cardiology and Other Societies on Cardiovascular Disease
Prevention in Clinical Practice. Eur J Prev Cardiol. 2016 ;23:NP1-NP96.

75. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the
Management of Dyslipidaemias. Eur Heart J 2016;37:2999-3058.

FIGURE LEGENDS

Figure 1. Lipid dysregulation triggers inflammatory and immune responses. AP-1:

Activator protein-1; **CCR2**: Chemokine receptor type-2; **COX-2**: Cyclooxygenase-2;

DC: Dendritic cells; **IKK**: I κ B kinase; **IL**: Interleukin IL: Interleukin; **IL1R**:

Interleukin-1 receptor; **INF γ** : Interferon- γ ; **JAK-STAT**: Janus kinase and Signal

Transducer Activator of Transcription Proteins; **JNK**: Jun kinase; **LDL**: low-density

lipoprotein; **mLDL**: modified LDL; **oxLDL**: oxidized LDL; **M ϕ** : macrophages; **MCP-**

1: Monocyte chemoattractant protein-1; **NF- κ B**: Nuclear factor- κ B; **NLR**: NOD-like

receptors; **PMN**: Polymorphonuclear; **PRR**: Pattern recognition receptors; **ROS**:

Reactive Oxygen species; **Scav-R**: Scavenger receptors; **SRA** and **SRB**: Scavenger

receptor class A and B; **TGF β** : Transforming growth factor- β ; **Th**: T helper cell; **TLR**:

Toll-like receptor; **TNF α** : Tumor necrosis factor- α ; **TNF-R**: Tumor necrosis factor-

receptor; **Treg**: T regulatory cell; **VCAM**: Vascular cell adhesion molecule.

Figure 2. Interleukin-1 β (IL1 β) as a connection in the mechanism of action of

LDL-lowering therapy and canakinumab. Modified LDL (**mLDL**) promotes the

synthesis of pro-IL1 β , while cholesterol crystals, among other stimuli, assemble the

components of the inflammasome activating caspase-1, leading to IL1 β synthesis. Then,

IL1 β synthesis may be inhibited by LDL-lowering therapies, while canakinumab binds

to IL1 β inhibiting its effects. **ASC**: adaptor protein; **CRP**: **C-reactive protein**. adaptor

protein; **NLRP3**: Nod-like receptor protein 3; other abbreviations as for figure 1.